Clinical trials: Vinblastine
Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
The Phase II NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with cisplatin based neoadjuvant chemotherapy in a clinical practice setting.
- Conditions
- Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
- Trial name
- NCT06960577
- Testing
- Durvalumab, Methotrexate, Vinblastine
- Where
- 59 sites in Australia, Brazil and 5 more
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Anti-CD30, Brentuximab
Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
This study will be held in the clinical oncology department, Helwan University, and Police Hospital, aiming to compare the efficacy and safety of anti-CD30 (BV) + Doxorubicin, Vinblastine, and Dacarbazine (AVD) versus the…
- Conditions
- Anti-CD30, Brentuximab, Doxorubicin, Vinblastine
- Trial name
- NCT07171827
- Testing
- Brentuximab Vedotin + Doxorubicin, Vinblastine, and Dacarbazine, Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Helwan University